{
  "trial_id": "NCT02388997",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Age",
      "label": "met",
      "evidence": "39-year-old man"
    },
    {
      "criterion": "Asthma diagnosis",
      "label": "met",
      "evidence": "history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness."
    },
    {
      "criterion": "FEV1 > 70%",
      "label": "met",
      "evidence": "Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted"
    },
    {
      "criterion": "Methacholine challenge test positive",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Total serum IgE level >= 125 IU/ml",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Positive test for allergic sensitization by prick skin testing",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Willingness to comply with study procedures and requirements",
      "label": "met",
      "evidence": "Participant must be willing to comply with study procedures and requirements."
    },
    {
      "criterion": "Age 18-40 years old",
      "label": "met",
      "evidence": "39-year-old man"
    },
    {
      "criterion": "Any gender, any racial/ethnic origin",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Asthma Control Test (ACT) score > 19",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Short-acting beta-agonist use < daily in last 4 weeks",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Positive Methacholine challenge test (i.e. at least 20% fall in FEV1 at a Methacholine concentration of \u226416 mg/ml) at screening protocol before enrollment.",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "exclusion": [
    {
      "criterion": "Inability or unwillingness to give written informed consent and HIPPA authorization",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Positive test for serum neutralizing antibody to rhinovirus (strain-16) at screening within 6 weeks",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "FVC < 80% predicted",
      "label": "not_met",
      "evidence": "Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted"
    },
    {
      "criterion": "Total IgE levels measured at screening protocol that are too elevated based on a subject's weight, to meet the recommendations for treatment with Omalizumab",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Chronic heart disease, lung diseases other than asthma, or other chronic illnesses, including primary and/or secondary immunodeficiency",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Hospitalization or treatment in the ER for asthma (unless the treatment involved the use of a bronchodilator only) during the last three years",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Subjects who have had one or more night time awakenings caused by asthma symptoms and/or who have needed their short acting beta-2 agonist (SABA; e.g., albuterol) inhaler for asthma symptoms > 4 days during the week before enrollment, or during the week before the virus challenge",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Intubation or management in the intensive care unit for an asthma exacerbation",
      "label": "not_met",
      "evidence": ""
    }
  ],
  "notes": "Patient has a history of asthma and is currently using inhaled corticosteroids. He has had symptoms of cough, wheezing, and shortness of breath that worsen throughout the work week.",
  "_meta": {
    "topic_id": "23",
    "trial_id": "NCT02388997",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}